Cantor Fitzgerald Estimates Precigen FY2025 Earnings

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Precigen in a report released on Thursday, March 20th. Cantor Fitzgerald analyst J. Kim expects that the biotechnology company will post earnings per share of ($0.27) for the year. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. The business had revenue of $1.19 million for the quarter, compared to analyst estimates of $1.30 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%.

PGEN has been the topic of several other reports. HC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Precigen in a research note on Thursday, March 20th. JMP Securities reaffirmed a "market outperform" rating and issued a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $7.00.

Remove Ads

Precigen Stock Performance

NASDAQ PGEN traded up $0.03 during trading on Monday, reaching $1.64. 1,423,186 shares of the company's stock were exchanged, compared to its average volume of 1,178,785. The company has a 50 day moving average price of $1.65 and a two-hundred day moving average price of $1.17. The stock has a market cap of $482.23 million, a P/E ratio of -2.98 and a beta of 1.58. Precigen has a 1 year low of $0.65 and a 1 year high of $2.17.

Hedge Funds Weigh In On Precigen

A number of institutional investors have recently modified their holdings of the business. Iridian Asset Management LLC CT grew its position in Precigen by 38.8% during the 4th quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company's stock worth $5,871,000 after purchasing an additional 1,465,962 shares during the last quarter. LexAurum Advisors LLC grew its holdings in shares of Precigen by 151.9% during the fourth quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company's stock worth $775,000 after buying an additional 417,055 shares during the last quarter. Geode Capital Management LLC increased its position in Precigen by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company's stock valued at $3,075,000 after acquiring an additional 149,829 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Precigen by 11.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company's stock worth $1,158,000 after acquiring an additional 127,467 shares during the period. Finally, HighTower Advisors LLC grew its stake in shares of Precigen by 186.8% in the 3rd quarter. HighTower Advisors LLC now owns 192,144 shares of the biotechnology company's stock valued at $179,000 after purchasing an additional 125,145 shares during the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.